Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 1Leukemia, Plasma Cell 1

Interventions

Dexamethasone 124Lenalidomide 72daratumumab 71Bortezomib 58pomalidomide 47carfilzomib 42Cyclophosphamide 39Calcium Dobesilate 36Specimen Handling 31Biopsy 29Magnetic Resonance Spectroscopy 26belantamab mafodotin 22isatuximab 21fludarabine 20iberdomide 18talquetamab 17Melphalan 15dexamethasone acetate 14dexamethasone 21-phosphate 14auricularum 14fludarabine phosphate 13elotuzumab 12selinexor 10tocilizumab 9X-Rays 8Nivolumab 8trametinib 7Whole-Body Irradiation 7Sirolimus 7Mycophenolic Acid 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Myeloma × High-Throughput Screening Assays × 90 days × Clear all
NCT03389347 2026-05-08

High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

University of Washington

Phase NA Active not recruiting
40 enrolled 7 charts
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡